Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ALNY · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and… NCT07575308 · Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB) ALN-6400 | ALNY Alnylam Pharmaceuticals | Phase 2 | Recruiting | 24 | Jun 30, 2027 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus NCT07465224 · Type 2 Diabetes Mellitus (T2DM) ALN-4324, Placebo | ALNY Alnylam Pharmaceuticals | Phase 2 | Active, not recruiting was recruiting | 24 | May 28, 2027 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate ALN-4285 in Adult Healthy Volunteers NCT07295717 · Healthy Volunteers ALN-4285, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1 | Recruiting | 76 | Dec 29, 2026 | Registry ↗ |
| Nov 13, 2026 | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy NCT06393712 · Cerebral Amyloid Angiopathy Placebo, ALN-APP | ALNY Alnylam Pharmaceuticals | Phase 2 | Active, not recruiting | 210 | Aug 9, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate ALN-6222 in Participants With Obesity NCT07624071 · Obesity ALN-6222, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1 | Recruiting | 88 | Dec 14, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated W… NCT07553442 · Hypertension ALN-AGT01 RVR, Placebo | ALNY Alnylam Pharmaceuticals | Phase 2 | Recruiting | 93 | Apr 1, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate ALN-4915 in Adult Healthy Volunteers NCT07535606 · Healthy Volunteers ALN-4915, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1 | Active, not recruiting | 36 | Jul 31, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate ALN-2232 in Participants With Obesity NCT07463846 · Obesity ALN-2232, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1/2 | Recruiting | 156 | Apr 28, 2027 | Registry ↗ |
| Nov 12, 2026 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Car… NCT07181109 · High Risk Cardiovascular Disease, Hypertension Zilebesiran, Placebo | ALNY Alnylam Pharmaceuticals | Phase 3 | Recruiting | 11,000 | Sep 23, 2030 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD NCT05231785 · Early-Onset Alzheimer Disease ALN-APP, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1 | Recruiting | 60 | Jan 11, 2029 | Registry ↗ |
| Nov 2, 2026 | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyop… NCT04153149 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy Vutrisiran, Sterile Normal Saline (0.9% NaCl) | ALNY Alnylam Pharmaceuticals | Phase 3 | Active, not recruiting | 655 | May 8, 2024 | Registry ↗ |
| Oct 27, 2026 | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma NCT06600321 · Advanced Hepatocellular Carcinoma, Metastatic Hepatocellula… ALN-BCAT, Pembrolizumab | ALNY Alnylam Pharmaceuticals | Phase 1 | Recruiting | 158 | Sep 30, 2027 | Registry ↗ |
| Oct 21, 2026 | A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy NCT06679946 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy Vutrisiran | ALNY Alnylam Pharmaceuticals | Phase 3 | Enrolling by invitation | 700 | Mar 31, 2028 | Registry ↗ |
| Oct 20, 2026 | TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyo… NCT07052903 · Transthyretin Amyloidosis With Cardiomyopathy Nucresiran, Sterile Normal Saline (0.9% NaCl) | ALNY Alnylam Pharmaceuticals | Phase 3 | Recruiting | 1,750 | May 28, 2030 | Registry ↗ |
| Oct 20, 2026 | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese P… NCT06845202 · Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mel… ALN-4324, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1/2 | Active, not recruiting | 105 | Aug 31, 2027 | Registry ↗ |
| Oct 15, 2026 | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangi… NCT06659640 · Hereditary Hemorrhagic Telangiectasia ALN-6400, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1/2 | Active, not recruiting | 89 | Jan 5, 2028 | Registry ↗ |
| Oct 15, 2026 | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease NCT06585449 · Huntington's Disease ALN-HTT02, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1 | Recruiting | 66 | Jul 5, 2028 | Registry ↗ |
| Oct 15, 2026 | Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of t… NCT06360289 · Hereditary Amyloidosis, Transthyretin-Related, Asymptomatic… Standard of Care | ALNY Alnylam Pharmaceuticals | — | Active, not recruiting | 346 | Dec 15, 2027 | Registry ↗ |
| Oct 13, 2026 | A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzh… NCT07636811 · Down Syndrome-Associated Alzheimer's Disease (DS-AD) Mivelsiran, Placebo | ALNY Alnylam Pharmaceuticals | Phase 2 | Recruiting | 58 | May 18, 2030 | Registry ↗ |
| Oct 13, 2026 | ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis… NCT04561518 · Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis | ALNY Alnylam Pharmaceuticals | — | Recruiting | 1,500 | Dec 31, 2033 | Registry ↗ |
| Oct 9, 2026 | DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a R… NCT07358078 · Transthyretin Amyloidosis With Cardiomyopathy | ALNY Alnylam Pharmaceuticals | — | Recruiting | 2,000 | Oct 23, 2030 | Registry ↗ |
| Oct 8, 2026 | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Tr… NCT07223203 · Hereditary Transthyretin-Mediated Amyloidosis With Polyneur… Nucresiran, Vutrisiran | ALNY Alnylam Pharmaceuticals | Phase 3 | Recruiting | 125 | Dec 27, 2027 | Registry ↗ |
| Oct 8, 2026 | A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease NCT07214727 · Alzheimer's Disease ALN-5288, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1 | Recruiting | 50 | Mar 6, 2030 | Registry ↗ |
| Oct 8, 2026 | Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program NCT05040373 · Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Poly… | ALNY Alnylam Pharmaceuticals | — | Recruiting | 10 | Oct 12, 2030 | Registry ↗ |
| Oct 6, 2026 | BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) NCT04982393 · Primary Hyperoxaluria Type 1 | ALNY Alnylam Pharmaceuticals | — | Active, not recruiting | 207 | Jan 2, 2029 | Registry ↗ |
| Oct 6, 2026 | ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) NCT04883905 · Acute Hepatic Porphyria | ALNY Alnylam Pharmaceuticals | — | Recruiting | 150 | Dec 31, 2030 | Registry ↗ |
| Apr 30, 2026 | A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension NCT06423352 · Mild to Moderate Hypertension Zilebesiran, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1/2 | Completed | 36 | Jul 17, 2025 | Registry ↗ |
| Apr 20, 2026 | APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiom… NCT03997383 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy Placebo, Patisiran | ALNY Alnylam Pharmaceuticals | Phase 3 | Completed | 360 | Jun 20, 2022 | Registry ↗ |
| Mar 2, 2026 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequa… NCT06272487 · High Cardiovascular Risk, Hypertension Zilebesiran, Placebo | ALNY Alnylam Pharmaceuticals | Phase 2 | Completed | 375 | Jun 19, 2025 | Registry ↗ |
| Feb 17, 2026 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04… NCT05661916 · Transthyretin-Mediated Amyloidosis ALN-TTRSC04, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1 | Completed | 96 | Sep 30, 2025 | Registry ↗ |
| Jan 12, 2026 | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis… NCT03759379 · Amyloidosis, Hereditary, Transthyretin Amyloidosis Patisiran, Vutrisiran | ALNY Alnylam Pharmaceuticals | Phase 3 | Completed | 164 | Nov 10, 2020 | Registry ↗ |
| Dec 23, 2025 | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension NCT04936035 · Hypertension Placebo, ALN-AGT01 | ALNY Alnylam Pharmaceuticals | Phase 2 | Completed | 394 | Apr 4, 2023 | Registry ↗ |
| Nov 3, 2025 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard… NCT05103332 · Hypertension Indapamide, Amlodipine | ALNY Alnylam Pharmaceuticals | Phase 2 | Completed | 663 | Dec 11, 2023 | Registry ↗ |
| Sep 19, 2025 | A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers NCT06675565 · Healthy Volunteers ALN-AGT01 RVR, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1 | Completed | 42 | Sep 8, 2025 | Registry ↗ |
| Jul 18, 2025 | A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 NCT04152200 · Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Lumasiran | ALNY Alnylam Pharmaceuticals | Phase 3 | Completed | 21 | May 18, 2021 | Registry ↗ |
| May 7, 2025 | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients… NCT05761301 · Type 2 Diabetes Mellitus (T2DM) ALN-KHK, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1/2 | Terminated | 49 | Apr 3, 2025 | Registry ↗ |
| Feb 14, 2025 | A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 NCT03905694 · Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1) Lumasiran | ALNY Alnylam Pharmaceuticals | Phase 3 | Completed | 18 | Jun 29, 2020 | Registry ↗ |
| Aug 12, 2024 | A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 NCT03681184 · Primary Hyperoxaluria Type 1 (PH1) Placebo, Lumasiran | ALNY Alnylam Pharmaceuticals | Phase 3 | Completed | 39 | Nov 5, 2019 | Registry ↗ |
| Aug 9, 2024 | A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) NCT03841448 · IgA Nephropathy (IgAN), Berger Disease Placebo, Cemdisiran | ALNY Alnylam Pharmaceuticals | Phase 2 | Terminated | 31 | Mar 17, 2022 | Registry ↗ |
| May 22, 2024 | A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Ele… NCT05161936 · Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Ur… Lumasiran, Placebo | ALNY Alnylam Pharmaceuticals | Phase 2 | Terminated | 2 | Nov 1, 2022 | Registry ↗ |
| May 20, 2024 | Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria NCT04056481 · Acute Hepatic Porphyria Givosiran | ALNY Alnylam Pharmaceuticals | — | Approved for marketing | — | — | Registry ↗ |
| May 20, 2024 | Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) NCT02939820 · TTR-mediated Amyloidosis, Amyloidosis, Hereditary patisiran (ALN-TTR02) | ALNY Alnylam Pharmaceuticals | — | Approved for marketing | — | — | Registry ↗ |
| May 17, 2024 | A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (… NCT04565717 · Nonalcoholic Steatohepatitis, NASH ALN-HSD, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1 | Terminated | 6 | Jan 6, 2023 | Registry ↗ |
| Apr 25, 2024 | An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hy… NCT03350451 · PH1, Primary Hyperoxaluria Lumasiran | ALNY Alnylam Pharmaceuticals | Phase 2 | Completed | 20 | Feb 7, 2023 | Registry ↗ |
| Apr 22, 2024 | Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Diseas… NCT03862807 · Amyloidosis, Familial, Transthyretin Amyloidosis Patisiran | ALNY Alnylam Pharmaceuticals | Phase 3 | Completed | 24 | Oct 6, 2020 | Registry ↗ |
| Apr 22, 2024 | ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute… NCT03338816 · Acute Hepatic Porphyria, Acute Intermittent Porphyria Givosiran, Placebo | ALNY Alnylam Pharmaceuticals | Phase 3 | Completed | 94 | Jan 31, 2019 | Registry ↗ |
| Apr 22, 2024 | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyr… NCT01960348 · TTR-mediated Amyloidosis, Amyloidosis, Hereditary patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl) | ALNY Alnylam Pharmaceuticals | Phase 3 | Completed | 225 | Aug 2017 | Registry ↗ |
| Apr 19, 2024 | The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in… NCT01961921 · TTR-mediated Amyloidosis ALN-TTR02 (patisiran) administered by intravenous (IV) infu… | ALNY Alnylam Pharmaceuticals | Phase 2 | Completed | 27 | Jul 2016 | Registry ↗ |
| Apr 19, 2024 | Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis NCT01617967 · TTR-mediated Amyloidosis Patisiran | ALNY Alnylam Pharmaceuticals | Phase 2 | Completed | 29 | Oct 2013 | Registry ↗ |
| Mar 29, 2024 | A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout NCT05256810 · Gout ALN-XDH, Placebo | ALNY Alnylam Pharmaceuticals | Phase 1/2 | Terminated | 44 | Jan 25, 2023 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:50 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances